Decoy-20 is a biologic commercialized by Indaptus Therapeutics, with a leading Phase I program in Metastatic Transitional (Urothelial) Tract Cancer. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Decoy-20’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Decoy-20 is expected to reach an annual total of $81 mn by 2040 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Decoy-20 Overview

Decoy-20 is under development for the treatment of solid tumors including colorectal cancer, bladder carcinoma, breast cancer, cervical cancer, non-Hodgkin lymphoma, adenoid cystic carcinoma, urothelial cancer, squamous cell carcinoma of the head and neck, adenocarcinoma of the pancreas, non-small cell lung cancer and hepatocellular carcinoma-associated HBV infection and human immunodeficiency virus (HIV) infection. It comprises of a single strain of killed and intact, non-pathogenic gram bacteria with reduced LPS-endotoxin activity. it is administered through intravenous route.

Indaptus Therapeutics Overview

Indaptus Therapeutics (Intec Pharma) is a biopharmaceutical company that develops drugs based on its proprietary Accordion Pill technology. The company’s product pipeline includes AP-CD/LD, a gastric-retentive drug used for treating Parkinson’s disease; AP-THC and AP-CBD, cannabinoid treatments for multiple pain indications such as low back pain, neuropathic pain and fibromyalgia. Its proprietary technology platform Accordion Pill, an oral drug delivery system is designed to improve the ability of existing drugs and drugs in development utilizing a gastric retention and specific release mechanism. The company works in collaboration with Merck Sharp and Dohme, LTS Lohmann Therapie-Systeme AG and other pharmaceutical companies to develop novel delivery systems for advancing its pipeline drug candidate. Intec Pharma is headquartered in Jerusalem, Israel.
The operating loss of the company was US$14.9 million in FY2022, compared to an operating loss of US$7.7 million in FY2021. The net loss of the company was US$14.3 million in FY2022, compared to a net loss of US$7.7 million in FY2021.

For a complete picture of Decoy-20’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.